<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03387904</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-11-II-01</org_study_id>
    <nct_id>NCT03387904</nct_id>
  </id_info>
  <brief_title>Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Randomized, Eploratory, Open Clinical Trial to Compare the Efficacy and Safety of Anlotinib Plus Irinotecan Versus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Zhengzhou University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effects and safety of Anlotinib Plus Irinotecan versus Irinotecan in patients
      with esophageal squamous cell carcinoma(ESCC).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress free survival (PFS)</measure>
    <time_frame>From randomization，each 42 days up to PD or death(up to 24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization until death (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Until initiation of new anticancer treatment(up to 24 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Anlotinib Plus Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib QD po.and Irinotecan Day 1,8 ivgtt. Both should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irinotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Irinotecan Day 1,8 ivgtt and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Plus Irinotecan</intervention_name>
    <description>Anlotinib QD po.and Irinotecan Day 1,8 ivgtt.</description>
    <arm_group_label>Anlotinib Plus Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan Day 1,8 ivgtt</description>
    <arm_group_label>Irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological documentation of esophageal squamous cell carcinoma;

          -  At least one measurable lesion (by RECIST1.1);

          -  Patients who have failed to a chemoradiation treatment;

          -  18-75，ECOG PS:0-1,Life expectancy of more than 12 weeks;

          -  No treated with molecular targeted drugs;

          -  Main organs function is normal;

          -  Patients should participate in the study voluntarily and sign informed consent;

        Exclusion Criteria:

          -  Allergic to anlotinib and/or its excipients;

          -  Patients with any severe and/or unable to control diseases，including：

               1. Blood pressure unable to be controlled ideally(systolic pressure ＞140
                  mmHg，diastolic pressure＞90 mmHg);

               2. Patients with Grade 2 or higher myocardial ischemia, myocardial infarction or
                  malignant arrhythmias(including QT≥450ms for male， QT≥470ms for female) and
                  patients with Grade 3 or higher congestive heart failure (NYHA Classification) or
                  LVEF＜50%;

          -  Patients with a clear Gastrointestinal bleeding tendency include the following
             situations: Local active ulcer lesions, and fecal occult blood (+ +) ; The patient had
             a history of black and hematemesis within 2 months;

          -  Patients with a bleeding tendency and INR&gt;1.5,APTT&gt;1.5 ULN ;

          -  Patients with factors that could affect oral medication (such as dysphagia，chronic
             diarrhea, intestinal obstruction etc.);

          -  Patients with active brain metastasis, cancerous meningitis, spinal cord compression
             patients or found in Screening stage;

          -  Patients treated with VEGFR inhibitor;

          -  Patients with drug abuse history and unable to get rid of or Patients with mental
             disorders;

          -  Patients participated in other anticancer drug clinical trials within 4 weeks;

          -  Patients with concomitant diseases which could seriously endanger their own safety or
             could affect completion of the study according to investigators' judgment;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Feng Wang, doctor</last_name>
    <phone>860013938244776</phone>
    <email>fengw010@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Feng Wang, doctor</last_name>
    </contact>
    <contact_backup>
      <last_name>Qingxia Fan, doctor</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2017</study_first_submitted>
  <study_first_submitted_qc>December 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Feng Wang</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Anlotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

